Novel therapies for treatment of multi-drug resistant acinetobacter baumannii skin infections

Virulence

Volumn 2, Issue 2, 2011, Pages

  Mihu, Mircea Radu ^a   Martinez, Luis R ^b,c  

^a Department of Internal Medicine   (United States)

^b LONG ISLAND UNIVERSITY   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Acinetobacter baumannii; Antimicrobial therapy; Multidrug resistant; Nosocomial infections

Indexed keywords

CIPROFLOXACIN; DORIPENEM; FINAFLOXACIN; NANOPARTICLE; NITRIC OXIDE; POLYMYXIN B; RIFAMPICIN; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; AFGHANISTAN; BACTERIAL PNEUMONIA; BACTERIAL SKIN DISEASE; BACTERIOPHAGE; GENE THERAPY; GENE TRANSFER; GENETIC ENGINEERING; HOSPITAL INFECTION; HOST PATHOGEN INTERACTION; HUMAN; IRAQ; MULTIDRUG RESISTANCE; NANOTECHNOLOGY; NONHUMAN; PHOTODYNAMIC THERAPY; RADIOIMMUNOTHERAPY; REVIEW; WOUND INFECTION; CROSS INFECTION; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; METHODOLOGY; MICROBIOLOGY; PATHOGENICITY; PHOTOCHEMOTHERAPY; SOLDIER; TISSUE TRANSPLANTATION;

ACINETOBACTER BAUMANNII; NEGIBACTERIA;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; AFGHANISTAN; ANTI-BACTERIAL AGENTS; BACTERIOPHAGES; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GENE THERAPY; HUMANS; IRAQ; MILITARY PERSONNEL; PHOTOCHEMOTHERAPY; PNEUMONIA, BACTERIAL; RADIOIMMUNOTHERAPY; TISSUE TRANSPLANTATION; WOUND INFECTION;

EID: 85046980084     PISSN: 21505594     EISSN: 21505608     Source Type: Journal    
DOI: 10.4161/viru.2.2.15061     Document Type: Review

References (89)

1. Gaynes R, Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 2005; 41:848-54.
2. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309-17.
3. Metan G, Alp E, Aygen B, Sumerkan B. Acinetobacter baumannii meningitis in post-neurosurgical patients: clinical outcome and impact of carbapenem resistance. J Antimicrob Chemother 2007; 60:197-9.
4. Núñez ML, Martínez-Toldos MC, Bru M, Simarro E, Segovia M, Ruiz J, et al. Appearance of resistance to meropenem during the treatment of a patient with meningitis by Acinetobacter. Scand J Infect Dis 1998; 30:421-3.
5. Olut AI, Erkek E. Early prosthetic valve endocarditis due to Acinetobacter baumannii: a case report and brief review of the literature. Scand J Infect Dis 2005; 37:919-21.
6. Anstey NM, Currie BJ, Hassell M, Palmer D, Dwyer B, Seifert H. Community-acquired bacteremic Acinetobacter pneumonia in tropical Australia is caused by diverse strains of Acinetobacter baumannii, with carriage in the throat in at-risk groups. J Clin Microbiol 2002; 40:685-6.
7. Leung WS, Chu CM, Tsang KY, Lo FH, Lo KF, Ho PL. Fulminant community-acquired Acinetobacter baumannii pneumonia as a distinct clinical syndrome. Chest 2006; 129:102-9.
8. Johnson EN, Burns TC, Hayda RA, Hospenthal DR, Murray CK. Infectious complications of open type III tibial fractures among combat casualties. Clin Infect Dis 2007; 45:409-15.
9. Murray CK, Yun HC, Griffith ME, Hospenthal DR, Tong MJ. Acinetobacter infection: what was the true impact during the Vietnam conflict? Clin Infect Dis 2006; 43:383-4.
10. Petersen K, Riddle MS, Danko JR, Blazes DL, Hayden R, Tasker SA, et al. Trauma-related infections in battlefield casualties from Iraq. Ann Surg 2007; 245:803-11.
11. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008; 21:538-82.
12. Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect 2006; 12:826-36.
13. Vila J, Marcos A, Marco F, Abdalla S, Vergara Y, Reig R, et al. In vitro antimicrobial production of beta-lactamases, aminoglycoside-modifying enzymes and chloramphenicol acetyltransferase by and susceptibility of clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 1993; 37:138-41.
14. Seifert H, Baginski R, Schulze A, Pulverer G. Antimicrobial susceptibility of Acinetobacter species. Antimicrob Agents Chemother 1993; 37:750-3.
15. Tankovic J, Legrand P, De Gatines G, Chemineau V, Brun-Buisson C, Duval J. Characterization of a hospital outbreak of imipenem-resistant Acinetobacter baumannii by phenotypic and genotypic typing methods. J Clin Microbiol 1994; 32:2677-81.
16. Turner PJ, Greenhalgh JM. The activity of meropenem and comparators against Acinetobacter strains isolated from European hospitals 1997-2000. Clin Microbiol Infect 2003; 9:563-7.
17. Li J, Rayner CR, Nation RL, Owen RJ, Spelman D, Tan KE, et al. Heteroresistance to colistin in multidrugresistant Acinetobacter baumannii. Antimicrob Agents Chemother 2006; 50:2946-50.
18. Peleg AY, Adams J, Paterson DL. Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii. Antimicrob Agents Chemother 2007; 51:2065-9.
19. Jawad A, Seifert H, Snelling AM, Heritage J, Hawkey PM. Survival of Acinetobacter baumannii on dry surfaces: comparison of outbreak and sporadic isolates. J Clin Microbiol 1998; 36:1938-41.
20. Martinez MA, Pinto ME, Giglio MS, Pommier J, Muñoz LM. [Identification and sensitivity of acinetobacter sp isolated from clinical specimens and hospital environment]. Rev Med Chil 1992; 120:1267-72.
21. Trilla A. Epidemiology of nosocomial infections in adult intensive care units. Intensive Care Med 1994; 20:1-4.
22. Bernards AT, Frénay HM, Lim BT, Hendriks WD, Dijkshoorn L, van Boven CP. Methicillin-resistant Staphylococcus aureus and Acinetobacter baumannii: an unexpected difference in epidemiologic behavior. Am J Infect Control 1998; 26:544-51.
23. Diomedi A. [Acinetobacter baumannii pandrug-resistant: update in epidemiological and antimicrobial managing issues]. Rev Chilena Infectol 2005; 22:298-320.
24. Dijkshoorn L, Van Vianen W, Degener JE, Michel MF. Typing of Acinetobacter calcoaceticus strains isolated from hospital patients by cell envelope protein profiles. Epidemiol Infect 1987; 99:659-67.
25. Joly-Guillou ML. Clinical impact and pathogenicity of Acinetobacter. Clin Microbiol Infect 2005; 11:868-73.
26. Hood MI, Jacobs AC, Sayood K, Dunman PM, Skaar EP. Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations. Antimicrob Agents Chemother 2010; 54:1029-41.
27. Lee K, Lee WG, Uh Y, Ha GY, Cho J, Chong Y, et al. VIM- and IMP-type metallo-beta-lactamase-producing Pseudomonas spp. and Acinetobacter spp. in Korean hospitals. Emerg Infect Dis 2003; 9:868-71.
28. Lee K, Yum JH, Yong D, Lee HM, Kim HD, Docquier JD, et al. Novel acquired metallo-beta-lactamase gene, bla(SIM-1), in a class 1 integron from Acinetobacter baumannii clinical isolates from Korea. Antimicrob Agents Chemother 2005; 49:4485-91.
29. Bou G, Cerveró G, Domínguez MA, Quereda C, Martínez-Beltrán J. Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme: high-level carbapenem resistance in A. baumannii is not due solely to the presence of beta-lactamases. J Clin Microbiol 2000; 38:3299-305.
30. Fournier PE, Vallenet D, Barbe V, Audic S, Ogata H, Poirel L, et al. Comparative genomics of multidrug resistance in Acinetobacter baumannii. PLoS Genet 2006; 2:7.
31. Vila J, Marti S, Sanchez-Cespedes J. Porins, efflux pumps and multidrug resistance in Acinetobacter baumannii. J Antimicrob Chemother 2007; 59:1210-5.
32. Tomaras AP, Dorsey CW, Edelmann RE, Actis LA. Attachment to and biofilm formation on abiotic surfaces by Acinetobacter baumannii: involvement of a novel chaperone-usher pili assembly system. Microbiology 2003; 149:3473-84.
33. Gaddy JA, Tomaras AP, Actis LA. The Acinetobacter baumannii 19606 OmpA protein plays a role in biofilm formation on abiotic surfaces and in the interaction of this pathogen with eukaryotic cells. Infect Immun 2009; 77:3150-60.
34. Loehfelm TW, Luke NR, Campagnari AA. Identification and characterization of an Acinetobacter baumannii biofilm-associated protein. J Bacteriol 2008; 190:1036-44.
35. Smith MG, Gianoulis TA, Pukatzki S, Mekalanos JJ, Ornston LN, Gerstein M, et al. New insights into Acinetobacter baumannii pathogenesis revealed by highdensity pyrosequencing and transposon mutagenesis. Genes Dev 2007; 21:601-14.
36. Russo TA, Luke NR, Beanan JM, Olson R, Sauberan SL, MacDonald U, et al. The K1 capsular polysaccharide of Acinetobacter baumannii strain 307-0294 is a major virulence factor. Infect Immun 2010; 78:3993-4000.
37. Dorsey CW, Beglin MS, Actis LA. Detection and analysis of iron uptake components expressed by Acinetobacter baumannii clinical isolates. J Clin Microbiol 2003; 41:4188-93.
38. Zimbler DL, Penwell WF, Gaddy JA, Menke SM, Tomaras AP, et al. Iron acquisition functions expressed by the human pathogen Acinetobacter baumannii. Biometals 2009; 22:23-32.
39. Jankowski S, Grzybek-Hryncewicz K, Fleischer M, Walczuk M. Susceptibility of isolates of Acinetobacter anitratus and Acinetobacter lwoffii to the bactericidal activity of normal human serum. FEMS Microbiol Immunol 1992; 4:255-60.
40. Lee JC, Koerten H, van den Broek P, Beekhuizen H, Wolterbeek R, van den Barselaar, et al. Adherence of Acinetobacter baumannii strains to human bronchial epithelial cells. Res Microbiol 2006; 157:360-6.
41. Jacobs AC, Hood I, Boyd KL, Olson PD, Morrison JM, Carson S, et al. Inactivation of phospholipase D diminishes Acinetobacter baumannii pathogenesis. Infect Immun 2010; 78:1952-62.
42. Choi CH, Lee EY, Lee YC, Park TI, Kim HJ, Hyun SH, et al. Outer membrane protein 38 of Acinetobacter baumannii localizes to the mitochondria and induces apoptosis of epithelial cells. Cell Microbiol 2005; 7:1127-38.
43. Erridge C, Moncayo-Nieto OL, Morgan R, Young M, Poxton IR. Acinetobacter baumannii lipopolysaccharides are potent stimulators of human monocyte activation via Toll-like receptor 4 signalling. J Med Microbiol 2007; 56:165-71.
44. Bassetti M, Repetto E, Righi E, Boni S, Diverio M, Molinari MP, et al. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 2008; 61:417-20.
45. Lee NY, Wang CL, Chuang YC, Yu WL, Lee HC, Chang CM, et al. Combination carbapenem-sulbactam therapy for critically ill patients with multidrug-resistant Acinetobacter baumannii bacteremia: four case reports and an in vitro combination synergy study. Pharmacotherapy 2007; 27:1506-11.
46. Higgins PG, Stubbings W, Wisplinghoff H, Seifert H. Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates. Antimicrob Agents Chemother 2010; 54:1613-5.
47. Urban C, Mariano N, Rahal JJ. In vitro double and triple bactericidal activities of doripenem, polymyxin B and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae and Escherichia coli. Antimicrob Agents Chemother 2010; 54:2732-4.
48. Garnacho-Montero J, Amaya-Villar R. Multiresistant Acinetobacter baumannii infections: epidemiology and management. Curr Opin Infect Dis 2010; 23:332-9.
49. Zavascki AP, Carvalhaes CG, Picão RC, Gales AC. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy. Expert Rev Anti Infect Ther 2010; 8:71-93.
50. Shankar R, He LK, Szilagyi A, Muthu K, Gamelli RL, Filutowicz M, et al. A novel antibacterial gene transfer treatment for multidrug-resistant Acinetobacter baumannii-induced burn sepsis. J Burn Care Res 2007; 28:6-12.
51. Thomas-Virnig CL, Centanni JM, Johnston CE, He LK, Schlosser SJ, Van Winkle KF, et al. Inhibition of multidrug-resistant Acinetobacter baumannii by nonviral expression of hCAP-18 in a bioengineered human skin tissue. Mol Ther 2009; 17:562-9.
52. Heilborn JD, Nilsson MF, Kratz G, Weber G, Sørensen O, Borregaard N, et al. The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J Invest Dermatol 2003; 120:379-89.
53. Yamasaki K, Schauber J, Coda A, Lin H, Dorschner RA, Schechter NM, et al. Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. FASEB J 2006; 20:2068-80.
54. Friedman AJ, Han G, Navati MS, Chacko M, Gunther L, Alfieri A, et al. Sustained release nitric oxide releasing nanoparticles: characterization of a novel delivery platform based on nitrite containing hydrogel/glass composites. Nitric Oxide 2008; 19:12-20.
55. Frank S, Kämpfer H, Wetzler C, Pfeilschifter J. Nitric oxide drives skin repair: novel functions of an established mediator. Kidney Int 2002; 61:882-8.
56. Mowbray M, Tan X, Wheatley PS, Rossi AG, Morris RE, Weller RB. Topically applied nitric oxide induces T-lymphocyte infiltration in human skin, but minimal inflammation. J Invest Dermatol 2008; 128:352-60.
57. Soneja A, Drews M, Malinski T. Role of nitric oxide, nitroxidative and oxidative stress in wound healing. Pharmacol Rep 2005; 57:108-19.
58. Mihu MR, Sandkovsky U, Han G, Friedman JM, Nosanchuk JD, Martinez LR. Nitric oxide releasing nanoparticles are therapeutic for Acinetobacter baumannii wound infections. Virulence 2010; 1:62-7.
59. Han G, Martinez LR, Mihu MR, Friedman AJ, Friedman JM, Nosanchuk JD. Nitric oxide releasing nanoparticles are therapeutic for Staphylococcus aureus abscesses in a murine model of infection. PLoS One 2009; 4:7804.
60. Martinez LR, Han G, Chacko M, Mihu MR, Jacobson M, Gialanella P, et al. Antimicrobial and healing efficacy of sustained release nitric oxide nanoparticles against Staphylococcus aureus skin infection. J Invest Dermatol 2009; 129:2463-9.
61. Nel A, Xia T, Mädler L, Li N. Toxic potential of materials at the nanolevel. Science 2006; 311:622-7.
62. Service RF. American Chemical Society meeting. Nanomaterials show signs of toxicity. Science 2003; 300:243.
63. Baroli B, Ennas MG, Loffredo F, Isola M, Pinna R, López-Quintela MA. Penetration of metallic nanoparticles in human full-thickness skin. J Invest Dermatol 2007; 127:1701-12.
64. Chang E, Thekkek N, Yu WW, Colvin VL, Drezek R. Evaluation of quantum dot cytotoxicity based on intracellular uptake. Small 2006; 2:1412-7.
65. Gamer AO, Leibold E, van Ravenzwaay B. The in vitro absorption of microfine zinc oxide and titanium dioxide through porcine skin. Toxicol In Vitro 2006; 20:301-7.
66. Afaq F, Abidi P, Matin R, Rahman Q. Cytotoxicity, pro-oxidant effects and antioxidant depletion in rat lung alveolar macrophages exposed to ultrafine titanium dioxide. J Appl Toxicol 1998; 18:307-12.
67. Hohr D, Steinfartz Y, Schins RP, Knaapen AM, Martra G, Fubini B, et al. The surface area rather than the surface coating determines the acute inflammatory response after instillation of fine and ultrafine TiO2 in the rat. Int J Hyg Environ Health 2002; 205:239-44.
68. Cabrales P, Han G, Nacharaju P, Friedman AJ, Friedman JM. Reversal of hemoglobin-induced vasoconstriction with sustained release of nitric oxide. Am J Physiol Heart Circ Physiol 2011; 300:49-56.
69. Lin NT, Chiou PY, Chang KC, Chen LK, Lai MJ. Isolation and characterization of phi AB2: a novel bacteriophage of Acinetobacter baumannii. Res Microbiol 2010; 161:308-14.
70. Castano AP, Mroz P, Wu MX, Hamblin MR. Photodynamic therapy plus low-dose cyclophosphamide generates antitumor immunity in a mouse model. Proc Natl Acad Sci USA 2008; 105:5495-500.
71. Demidova TN, Hamblin MR. Photodynamic therapy targeted to pathogens. Int J Immunopathol Pharmacol 2004; 17:245-54.
72. Dai T, Tegos GP, Lu Z, Huang L, Zhiyentayev T, Franklin MJ, et al. Photodynamic therapy for Acinetobacter baumannii burn infections in mice. Antimicrob Agents Chemother 2009; 53:3929-34.
73. Jori G. Photodynamic therapy of microbial infections: state of the art and perspectives. J Environ Pathol Toxicol Oncol 2006; 25:505-19.
74. Merchat M, Spikes JD, Bertoloni G, Jori G. Studies on the mechanism of bacteria photosensitization by meso-substituted cationic porphyrins. J Photochem Photobiol B 1996; 35:149-57.
75. Malik Z, Ladan H, Nitzan Y. Photodynamic inactivation of Gram-negative bacteria: problems and possible solutions. J Photochem Photobiol B 1992; 14:262-6.
76. Milenic DE, Brady ED, Brechbiel MW. Antibodytargeted radiation cancer therapy. Nat Rev Drug Discov 2004; 3:488-99.
77. Dadachova E, Casadevall A. Antibodies as delivery vehicles for radioimmunotherapy of infectious diseases. Expert Opin Drug Deliv 2005; 2:1075-84.
78. Dadachova E, Nakouzi A, Bryan RA, Casadevall A. Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection. Proc Natl Acad Sci USA 2003; 100:10942-7.
79. Dadachova E, Howell RW, Bryan RA, Frenkel A, Nosanchuk JD, Casadevall A. Susceptibility of the human pathogenic fungi Cryptococcus neoformans and Histoplasma capsulatum to gamma-radiation versus radioimmunotherapy with alpha- and beta-emitting radioisotopes. J Nucl Med 2004; 45:313-20.
80. Dadachova E, Burns T, Bryan RA, Apostolidis C, Brechbiel MW, Nosanchuk JD, et al. Feasibility of radioimmunotherapy of experimental pneumococcal infection. Antimicrob Agents Chemother 2004; 48:1624-9.
81. Rivera J, Nakouzi A, Abboud N, Revskaya E, Goldman D, Collier RJ, et al. A monoclonal antibody to Bacillus anthracis protective antigen defines a neutralizing epitope in domain 1. Infect Immun 2006; 74:4149-56.
82. Phaeton R, Wang XG, Einstein MH, Goldberg GL, Casadevall A, Dadachova E. The influence of proteasome inhibitor MG132, external radiation and unlabeled antibody on the tumor uptake and biodistribution of (188)re-labeled anti-E6 C1P5 antibody in cervical cancer in mice. Cancer 2010; 116:1067-74.
83. Dadachova E, Patel MC, Toussi S, Apostolidis C, Morgenstern A, Brechbiel MW, et al. Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins. PLoS Med 2006; 3:427.
84. Macklis RM. How and why does radioimmunotherapy work? Int J Radiat Oncol Biol Phys 2004; 59:1269-71.
85. Islam AH, Singh KK, Ismail A. Demonstration of an outer membrane protein that is antigenically specific for Acinetobacter baumannii. Diagn Microbiol Infect Dis 2011; 69:38-44.
86. McConnell MJ, Domínguez-Herrera J, Smani Y, López-Rojas R, Docobo-Pérez F, Pachón J. Vaccination with outer membrane complexes elicits rapid protective immunity to multidrug-resistant Acinetobacter baumannii. Infect Immun 2011; 79:518-26.
87. Goel VK, Kapil A. Monoclonal antibodies against the iron regulated outer membrane Proteins of Acinetobacter baumannii are bactericidal. BMC Microbiol 2001; 1:16.
88. Wang HM, Chen Cy, Chen HA, Huang WC, Lin WR, Chen TC, et al. Zingiber officinale (ginger) compounds have tetracycline-resistance modifying effects against clinical extensively drug-resistant Acinetobacter baumannii. Phytother Res 2010; 24:1825-30.
89. Fernandes Júnior A, Balestrin EC, Betoni JE, Orsi Rde O, da Cunha Mde L, Montelli AC. Propolis: anti-Staphylococcus aureus activity and synergism with antimicrobial drugs. Mem Inst Oswaldo Cruz 2005; 100:563-6.